CDK2 and non-small cell lung carcinoma: Moreover, toward PACCs with excessive centrosomes, CDK2 inhibitors exhibit selective lethality and spare normal cells with two centrosomes.[97] Mifepristone, a well‐known anti‐progestin steroid, is a cytostatic compound targeting CDK2.[98] Mifepristone exposure greatly impairs the escape of PACCs from DNA damage caused by cisplatin, as well as the action of poly (ADP‐ribose) polymerase inhibitors (PARPi), and is effective in halting tumor progression in non‐small cell lung cancer (NSCLC) and HGSOC.[15, 99]